Litalir en es it fr

Litalir Brand names, Litalir Analogs

Litalir Brand Names Mixture

  • No information avaliable

Litalir Chemical_Formula


Litalir RX_link

Litalir fda sheet

Litalir FDA

Litalir msds (material safety sheet)

Litalir MSDS

Litalir Synthesis Reference

No information avaliable

Litalir Molecular Weight

76.0547 g/mol

Litalir Melting Point

142-146 oC

Litalir H2O Solubility

1E+006 mg/L

Litalir State


Litalir LogP


Litalir Dosage Forms


Litalir Indication

For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.

Litalir Pharmacology

Hydroxyurea has dose-dependent synergistic activity with cisplatin in vitro. In vivo Hydroxyurea showed activity in combination with cisplatin against the LX-1 and CALU-6 human lung xenografts, but minimal activity was seen with the NCI-H460 or NCI-H520 xenografts. Hydroxyurea was synergistic with cisplatin in the Lewis lung murine xenograft. Sequential exposure to Hydroxyurea 4 hours before cisplatin produced the greatest interaction.

Litalir Absorption

Well absorbed from the gastrointestinal tract.

Litalir side effects and Toxicity

Oral, mouse: LD50 = 7330 mg/kg; Oral, rat: LD50 = 5760 mg/kg

Litalir Patient Information

HYDREA is a medication that must be handled with care. People who are not taking HYDREA should not be exposed to it. If the powder from the capsule is spilled, it should be wiped up immediately with a damp disposable towel and discarded in a closed container, such as a plastic bag. The medication should be kept away from children and pets.

Litalir Organisms Affected

Humans and other mammals